Aclaris says Phase 2 ADMIRATION trial of bosakitug missed its primary endpoint in atopic dermatitis
The company reported the trial failed to hit its EASI-based primary and secondary endpoints, but said it will keep prioritizing its oral ITK inhibitors and bispecific antibody ATI-052.
SEC filing